Author’s response to reviews

Title: Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission

Authors:

Weihui Sun (qdsycymyy@sina.com)
Zhao Shangfei (qdslyydong@163.com)
Ma Lei (maleipretty@126.com)
Hao Anhua (qingyi820329@163.com)
Zhao Bo (geyapp@126.com)
Zhou Lin (zlxyzzl@163.com)
Qu Qiaoyan (mcclz_2001@163.com)
Song Mingquan (songmingquan625@sina.com)
Xin Yongning (xinyongning@163.com)

Version: 2 Date: 11 Jan 2017

Author’s response to reviews:

Responses to the Reviewer

1. Please check "HBV DNA≥ 1.0 DN7 copies/mL" in ABSTRACT.
Response: Thank the reviewer to point out the mistake. We have change as followed: HBV DNA ≥1.0×10^7 copies/mL.

2. Please change "HVL" to "high viral load" in DISCUSSION
Response: We agree the suggestion and we have changed “HVL” to “high viral load”.

3. Please check the sentence "Therefore, it is worth considering that whether risk the risk of resistance to prolong telbivudine treatment after delivery” in DISCUSSION.
Response: We thank the reviewer for the comment. We have rewritten the sentence as followed: Therefore, whether or not to continue telbivudine treatment after delivery requires careful consideration.

4. In Table 2, please change "HBV DNA viral load" to "HBV DNA viral loads, log10 copies/ml".

Response: Thank the reviewer for the comment, we have changed to "HBV DNA viral loads, log10 copies/ml" in Table 2.

5. In Table 2, please change "ALT levels" to "ALT levels, IU/mL".

Response: Thank the reviewer for the comment, we have changed to "ALT levels, IU/mL" in Table 2.